Dr Carl Dolman
With an academic background focussed on the production, purification and characterisation of monoclonal antibodies, Carl Dolman began working with NIBSC in 1996 and has since become the Study Director of the Therapeutic Immunoglobulins and Allergens area. This is now part of the larger Molecular Immunology Section within the Biotherapeutics Group.
His team is responsible for the control testing of several hundred batches of therapeutic immunoglobulin per year, as well as a few allergen products that include grass pollen, bee and wasp venom. His group has also participated in many European Directorate for the European Directorate for the Quality of Medicines and Healthcare (EDQM) run biological standardisation programs (BSP: 039, 044, 068, 071, 099, 108, 122, 160) such as the establishment of Human Immunoglobulin for Electrophoresis BRP Batch 4 (BSP160).
Carl has been an active participant at annual OMCL meetings since 1999 and became an elected member of the Advisory Group to the General OMCL network (AdG-GEON) in 2011 for four years. He is responsible for extraction of the control testing data for the NIBSC annual OMCL reports for both blood products and vaccines.
Present research interests include; HPLC analysis of biosimilars, purification of virus particles, affinity purification and analysis of HIV envelope proteins; study of aggregate and dimer levels in therapeutic immunoglobulins, purification of monoclonal antibodies for use as international standards. He is currently working on establishing an HPLC aggregate standard for use in the immunoglobulins control testing assay ‘Distribution of molecular size’ and has taken part in recent EDQM organised Proficiency Testing Schemes (PTS) for this assay (PTS202).
Another major role for Carl is the administrator role of the Institute’s batch release database “CT-LIMS” that handles sample information from receipt at NIBSC through to testing, results entry and authorisation including the automatic dispatch of a National Control Authority release certificate to the manufacturer.